Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 5e. TASK NUMBER 5f. WORK UNIT NUMBER
REPORT DATE
01-08-2006
REPORT TYPE
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBERDartmouth College Hanover, NH 03755
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTESOriginal contains colored plates: ALL DTIC reproductions will be in black and white.
ABSTRACTThis project aimed to determine the importance of "S14", a nuclear protein that signals for lipid synthesis, in breast cancer. Our aims were first, to develop a model of anti-S14 breast cancer therapy. Intratumoral adenoviral delivery of an S14-antisense gene into human breast cancer cell xenografts significantly inhibited tumor growth, and we verified the specificity of this effect using siRNA. We identified two siRNAs that knockdown S14 protein in breast cancer cells, and found them to be cytotoxic. Second, to define the structure of the S14 multimer. S14 proved very difficult to crystallize. We therefore used NMR and computer modeling to discern the structure of the S14 tetramerization domain, and identified key residues for multimer assembly by mutagenesis. Third, to define the utility of S14 as a clinical marker. We produced S14 antibodies for immunohistochemistry. This revealed strong associations of S14 staining with tumor size and grade, and a striking power to predict tumor recurrence. Thus, S14 is a driver and a marker of virulent breast cancer that identifies cases that are likely to recur. 4 Introduction This project is aimed at defining the potential of protein "S14" as a therapeutic target in breast cancer. S14 is a small, primarily nuclear protein that signals for increased fatty acid synthesis in normal tissues, such as lactating mammary, liver and adipose, in response to fuel-related hormones and nutrients. Most breast cancers have high rates of lipid synthesis, and this promotes their growth and survival. ...